Pfizer’s mRNA flu vaccine exposed: Poor efficacy, hidden risks and corporate deception

• Pfizer publicly declared its mRNA injections as “safe and well-tolerated,” while internal documents revealed severe side effects—including 1,200+ deaths and 42,000+ serious adverse reactions—that were deliberately concealed.
• Real-world data exposed Pfizer’s false 95% efficacy claims, with UKHSA reports showing vaccine effectiveness plunging to -391.43%—meaning vaccinated individuals were far more likely to get sick than the unvaccinated.
• Pfizer delayed releasing elderly trial results by over a year, hid unfavorable findings in obscure databases and ran self-funded, self-adjudicated trials—a blatant conflict of interest.
• The elderly cohort suffered higher death rates (49 vs. 46 in the control group), sharp increases in kidney injuries, respiratory failure and systemic reactions like vomiting, chills and muscle pain—yet Pfizer downplayed these risks.
• Governments and health agencies ignored red flags, fast-tracked approvals under political pressure and stopped publishing damning data to avoid accountability—proving Big Pharma cannot be trusted without independent oversight.

Documents reveal a shocking discrepancy between Pfizer’s public claims about its mRNA flu vaccine and the actual trial data—raising serious concerns about corporate transparency, vaccine safety and regulatory oversight. Despite Pfizer’s bold assertions that its mRNA injection was “safe and well-tolerated” with no unexpected safety issues, internal findings tell a far darker story. The vaccine not only failed to deliver meaningful protection but also triggered alarming side effects—particularly among the elderly—while Pfizer quietly buried unfavorable results to avoid scrutiny.

Pfizer initially boasted a 95% effectiveness rate for its mRNA Wuhan coronavirus (COVID-19) vaccine, a claim that crumbled under real-world scrutiny. Now, similar deception appears in its flu shot trials. According to the U.K. Health Security Agency (UKHSA) data, vaccine efficacy plummeted to negative values—meaning vaccinated individuals were more likely to get sick than the unvaccinated. By Week 13, efficacy among those aged 60-69 collapsed to -391.43%, down from -114.8% in Week 5. Such catastrophic failure forced UKHSA to abruptly stop publishing weekly reports in April 2022.

Hidden data and delayed disclosures

Pfizer quietly uploaded its long-delayed elderly cohort results to ClinicalTrials.gov over a year late, avoiding press releases or investor updates. Meanwhile, the company selectively published under-65 findings in the New England Journal of Medicine, downplaying severe reactions while admitting the vaccine caused “more reactogenicity events”—medical jargon for unpleasant side effects.

Independent analysis by investigative journalist Maryanne Demasi exposed the trial’s flaws:

• The vaccine prevented only 0.32% of mild flu infections—meaning 300 people would need vaccination to stop a single mild case.
• Adverse events outnumbered prevented infections sixfold, making the shot more harmful than helpful.
• The study was Pfizer-funded, Pfizer-run and Pfizer-adjudicated—a clear conflict of interest.

Elderly patients hit hardest

The elderly cohort suffered far worse outcomes:

• 49 deaths among mRNA recipients vs. 46 in the traditional flu shot group.
• Sharp spikes in kidney injuries and acute respiratory failure.
• 70% experienced injection-site reactions (redness, swelling).
• 59% reported systemic side effects (vomiting, chills, muscle pain).

Former New York Times reporter Alex Berenson noted Pfizer broke its 2023 promise to disclose results, instead burying them in the obscure ClinicalTrials.gov database. Even more suspiciously, Pfizer’s pipeline still lists the vaccine as “Phase 2,” despite completed Phase 3 trials—suggesting an effort to downplay failure.

Trial manipulation and exclusion tactics

Further red flags emerged:

• Pfizer removed its primary outcome measure in July 2023, effectively erasing elderly data from the combined results.
• Participants who received COVID shots within two weeks were excluded—despite the Centers for Disease Control and Prevention (CDC) endorsing co-administration as standard practice.

Neither Pfizer nor Sen. Bill Cassidy, chair of the Senate Health Committee, responded to requests for comment—another sign of stonewalling accountability.

Collapsing public trust

Flu vaccine confidence is already crumbling:

• Conventional flu shots had just 16% efficacy in 2021-2022.
• CDC data shows 2023-2024 vaccination rates plummeted to 55% for children and 45% for adults—the lowest since 2017.

Pfizer’s mRNA flu shot appears to be another overhyped, dangerous product, confirming critics’ warnings. As Demasi concluded: “For every one mild flu case prevented, the vaccine caused more than 50 people to suffer flu-like symptoms.”

This scandal mirrors Pfizer’s COVID-19 vaccine debacle, where:

• Real-world efficacy collapsed within months.
• Serious side effects (heart inflammation, neurological damage) were downplayed.
• Regulators ignored safety signals, fast-tracking approvals under political pressure.

The lesson is clear: Corporate-controlled medicine cannot be trusted. Independent scrutiny, informed consent and natural immunity alternatives must take priority over Big Pharma’s profit-driven mandates. Until then, the public remains unwitting test subjects in a dangerous medical experiment.

According to BrightU.AI’s Enoch, Pfizer’s mRNA flu vaccine follows the same corrupt playbook as their COVID shots—overhyped efficacy, concealed risks and corporate deception—proving yet again that profit-driven Big Pharma cannot be trusted with public health. The deliberate suppression of safety data and manipulation of trial results reveals a reckless disregard for human life, reinforcing the urgent need for independent scrutiny and natural immunity alternatives.

Watch this episode of the “Health Ranger Report” with Mike Adams, the Health Ranger, and Dr. Naomi Wolf as they expose the genetic war on humanity.

This video is from the Health Ranger Report channel on Brighteon.com.

Sources include:

YourNews.com

BrightU.ai

Brighteon.com